Atara Biotherapeutics, Inc. (ATRA)

Market Cap	63.00M
Revenue (ttm)	199.73M
Net Income (ttm)	-15.64M
Shares Out	6.80M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	5.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,905
Open	9.29
Previous Close	9.30
Day's Range	8.77 - 9.62
52-Week Range	5.01 - 18.71
Beta	0.18
Analysts	Buy
Price Target	17.75 (+91.48%)
Earnings Date	Aug 11, 2025

About ATRA

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queenslan...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2014
• Employees: 153
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRA
• Website: https://www.atarabio.com

Financial Performance

In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price target is $17.75, which is an increase of 91.48% from the latest price.

Price Target

$17.75

(91.48% upside)

Analyst Consensus: Buy